Current
65.4×
5-Year Average
184.7×
All-Time High
340.9×
All-Time Low
61.3×
EV/EBITDA daily chart for Alnylam Pharmaceuticals (ALNY)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
EV/EBITDA is not shown for periods when TTM EBITDA was negative.
Historical EV/EBITDA for Alnylam Pharmaceuticals (ALNY) from 2003 to 2025
| 2025 | $52.58B | $472.68M | 107.8× | — | |
| 2024 | $30.26B | −$178.94M | — | — | |
| 2023 | $24.04B | −$258.24M | — | — | |
| 2022 | $29.29B | −$926.56M | — | — | |
| 2021 | $20.31B | −$661.56M | — | — | |
| 2020 | $15.11B | −$736.33M | — | — | |
| 2019 | $12.87B | −$862.38M | — | — | |
| 2018 | $7.37B | −$809.26M | — | — | |
| 2017 | $12.21B | −$486.72M | — | — | |
| 2016 | $3.21B | −$409.46M | — | — | |
| 2015 | $7.99B | −$276.96M | — | — | |
| 2014 | $7.46B | −$172.29M | — | — | |
| 2013 | $4.05B | −$82.71M | — | — | |
| 2012 | $945.73M | −$55.63M | — | — | |
| 2011 | $376.61M | −$49.69M | — | — | |
| 2010 | $416.02M | −$41.02M | — | — | |
| 2009 | $737.75M | −$42.28M | — | — | |
| 2008 | $1.02B | −$18.93M | — | — | |
| 2007 | $1.18B | −$89.09M | — | — | |
| 2006 | $799.85M | −$36.46M | — | — | |
| 2005 | $401.17M | −$40.35M | — | — | |
| 2004 | $152.65M | −$29.82M | — | — | |
| 2003 | $9.95M | −$23.59M | — | — |
- 2025107.8×
- 2024—
- 2023—
- 2022—
- 2021—
- 2020—
- 2019—
- 2018—
- 2017—
- 2016—
- 2015—
- 2014—
- 2013—
- 2012—
- 2011—
- 2010—
- 2009—
- 2008—
- 2007—
- 2006—
- 2005—
- 2004—
- 2003—
About EV/EBITDA at Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals (ALNY) EV/EBITDA ratio is 65.4× as of June 5, 2026. The 5-year average is 184.7×. The sector median currently stands at 15.0×. The current ratio is at the 11th percentile of its own 10-year history.
Alnylam Pharmaceuticals (ALNY) historical EV/EBITDA ratio has ranged from a low of 61.3× (2026) to a high of 340.9× (2025) in the available daily series.
The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.
Alnylam Pharmaceuticals EV/EBITDA by Year
Alnylam Pharmaceuticals EV/EBITDA 2025: 107.8×
Alnylam Pharmaceuticals (ALNY) EV/EBITDA ratio in 2025 was 107.8×.
EV is calculated as Market Cap + Total Debt − Cash & Short-Term Investments (simplified). Minority interest and preferred equity are excluded due to data availability. This is consistent with the methodology used by most public financial data providers.
Sector peers by EV/EBITDA — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by EV/EBITDA — table
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by EV/EBITDA ratio.
| 13.9× | |
| 13.6× | |
| 13.6× | |
| 13.2× | |
| 12.9× | |
| 12.9× | |
| 12.7× | |
| 12.4× | |
| 12.0× | |
| 11.7× | |
| 11.5× | |
| 11.5× | |
| 11.2× | |
| 10.5× | |
| 10.0× | |
| 8.8× | |
| 8.5× | |
| 8.2× | |
| 7.9× | |
| 7.8× | |
| 6.8× | |
| 6.5× | |
| 5.8× | |
| 5.7× | |
| 4.5× |
- 13.6×
- 13.2×
- 12.9×
- 12.4×
- 12.0×
- 11.7×
- 11.5×
- 10.5×
- 10.0×
- 8.5×
- 8.2×
- 7.9×
- 7.8×
- 5.8×
- 4.5×
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric